Stifel Financial Corp Has $530,000 Stock Position in Codexis, Inc. (NASDAQ:CDXS)

Stifel Financial Corp reduced its position in Codexis, Inc. (NASDAQ:CDXS) by 38.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 172,186 shares of the biotechnology company’s stock after selling 106,466 shares during the period. Stifel Financial Corp’s holdings in Codexis were worth $530,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. FMR LLC boosted its stake in Codexis by 1.2% in the 3rd quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock worth $13,851,000 after purchasing an additional 51,822 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Codexis by 23.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after purchasing an additional 209,207 shares in the last quarter. abrdn plc boosted its position in shares of Codexis by 62.5% in the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock worth $2,465,000 after buying an additional 307,762 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Codexis by 34.5% during the second quarter. Dimensional Fund Advisors LP now owns 340,762 shares of the biotechnology company’s stock valued at $1,056,000 after buying an additional 87,457 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Codexis by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 284,166 shares of the biotechnology company’s stock valued at $881,000 after buying an additional 32,138 shares during the period. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Price Performance

Shares of NASDAQ:CDXS opened at $4.97 on Friday. The firm has a market cap of $404.45 million, a price-to-earnings ratio of -5.71 and a beta of 2.15. Codexis, Inc. has a 1 year low of $2.53 and a 1 year high of $6.08. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The business has a fifty day simple moving average of $4.35 and a 200 day simple moving average of $3.53.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The firm had revenue of $12.83 million for the quarter, compared to analysts’ expectations of $11.64 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. During the same period last year, the business earned ($0.26) earnings per share. As a group, sell-side analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CDXS has been the subject of a number of research reports. Benchmark restated a “hold” rating on shares of Codexis in a research report on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Codexis in a report on Friday, November 22nd.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.